{"shortAnswer":"Liraglutide is FDA-approved as Victoza and Saxenda, and as generics, with a prescription. The evidence grade is strong-human for blood sugar, weight and heart risk in diabetes. It is still on FDA's shortage list. Pharmacy copies are not approved.","url":"https://peptideindex.ai/compound/liraglutide","status":"fda-approved","statusCheckedAt":"2026-10-25T06:23:45.889Z","statusStale":false,"regulatoryAsOf":"2026-10-24","verified":"2026-10-25T06:23:45.924Z","primarySourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"f5e04caf-18cb-403e-8e37-2579a7a74fd7","object":"compound","slug":"liraglutide","name":"Liraglutide","attrs":{"name":"Liraglutide","class":"glp-1-agonist","access":[{"type":"approved-product","detail":"Approved by FDA and sold with a prescription as a daily shot for type 2 diabetes.","indication":"Type 2 diabetes in adults and children 10 and older, and lower heart risk in adults with type 2 diabetes and heart disease.","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","brand_names":["Victoza"],"manufacturer":"Novo Nordisk"},{"type":"approved-product","detail":"Approved by FDA and sold with a prescription as a daily shot for weight loss.","indication":"Weight loss with diet and exercise in adults and children 12 and older with obesity who weigh more than 60 kg, and in adults with overweight and a related health problem.","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143","brand_names":["Saxenda"],"manufacturer":"Novo Nordisk"},{"type":"lawful-compounding","detail":"Liraglutide is still on FDA's drug shortage list. While it stays there, outsourcing facilities may make it from raw powder. FDA has proposed keeping it off their list of allowed raw ingredients, so this path would close when the shortage ends. The proposal is not final.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"}],"dosing":"From the Victoza label and the Saxenda label. Both are shots under the skin once a day. Victoza starts at 0.6 mg a day for one week, then 1.2 mg a day, and the most is 1.8 mg a day. The Saxenda label says Saxenda starts at 0.6 mg a day and goes up each week until it reaches 3 mg a day. Children who cannot take 3 mg may stay at 2.4 mg a day. The prescriber sets the dose.","trials":[{"nct":"NCT07787936","url":"https://clinicaltrials.gov/study/NCT07787936","phase":"Not stated","title":"GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry","status":"not-yet-recruiting","sponsor":"Miedziowe Centrum Zdrowia SA","countries":["Poland"],"us_states":[]},{"nct":"NCT07027969","url":"https://clinicaltrials.gov/study/NCT07027969","phase":"Phase 4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"not-yet-recruiting","sponsor":"Ali Aminian","countries":["United States"],"us_states":["Ohio"]},{"nct":"NCT07881783","url":"https://clinicaltrials.gov/study/NCT07881783","phase":"Not stated","title":"A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy","status":"not-yet-recruiting","sponsor":"Novartis Pharmaceuticals","countries":[],"us_states":[]},{"nct":"NCT07702461","url":"https://clinicaltrials.gov/study/NCT07702461","phase":"Not stated","title":"Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists","status":"recruiting","sponsor":"Ohio State University","countries":["United States"],"us_states":["Ohio"]},{"nct":"NCT06726577","url":"https://clinicaltrials.gov/study/NCT06726577","phase":"Phase 1/Phase 2","title":"TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis","status":"recruiting","sponsor":"Talengen Institute of Life Sciences, Shenzhen, P.R. China.","countries":["China"],"us_states":[]},{"nct":"NCT07301437","url":"https://clinicaltrials.gov/study/NCT07301437","phase":"Phase 4","title":"RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.","status":"not-yet-recruiting","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","countries":[],"us_states":[]},{"nct":"NCT07107334","url":"https://clinicaltrials.gov/study/NCT07107334","phase":"Phase 2","title":"A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia","status":"recruiting","sponsor":"University of Florida","countries":["United States"],"us_states":["Florida"]},{"nct":"NCT06836284","url":"https://clinicaltrials.gov/study/NCT06836284","phase":"Not applicable","title":"The Evira Study: Additional Support During Obesity Treatment","status":"recruiting","sponsor":"Karolinska Institutet","countries":["Sweden"],"us_states":[]},{"nct":"NCT07225816","url":"https://clinicaltrials.gov/study/NCT07225816","phase":"Phase 1","title":"Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)","status":"recruiting","sponsor":"Novo Nordisk A/S","countries":["United States"],"us_states":["California"]},{"nct":"NCT06976619","url":"https://clinicaltrials.gov/study/NCT06976619","phase":"Phase 2","title":"The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes","status":"recruiting","sponsor":"Mayo Clinic","countries":["United States"],"us_states":["Minnesota"]},{"nct":"NCT06903923","url":"https://clinicaltrials.gov/study/NCT06903923","phase":"Phase 2","title":"Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy","status":"recruiting","sponsor":"University of Virginia","countries":["United States"],"us_states":["Virginia"]},{"nct":"NCT07042672","url":"https://clinicaltrials.gov/study/NCT07042672","phase":"Not stated","title":"Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","status":"recruiting","sponsor":"Haukeland University Hospital","countries":["Norway"],"us_states":[]},{"nct":"NCT07094568","url":"https://clinicaltrials.gov/study/NCT07094568","phase":"Not stated","title":"Tirzepatide vs Liraglutide in Bone","status":"recruiting","sponsor":"National and Kapodistrian University of Athens","countries":["Greece"],"us_states":[]},{"nct":"NCT06742710","url":"https://clinicaltrials.gov/study/NCT06742710","phase":"Phase 4","title":"Liraglutide Treatment in Obese Infertile PCOS Women","status":"recruiting","sponsor":"Peking University Third Hospital","countries":["China"],"us_states":[]},{"nct":"NCT07029009","url":"https://clinicaltrials.gov/study/NCT07029009","phase":"Phase 2","title":"Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)","status":"recruiting","sponsor":"Mansa","countries":["United States"],"us_states":["Ohio"]},{"nct":"NCT06865365","url":"https://clinicaltrials.gov/study/NCT06865365","phase":"Phase 4","title":"Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone","status":"not-yet-recruiting","sponsor":"Medical University of Vienna","countries":[],"us_states":[]},{"nct":"NCT07244003","url":"https://clinicaltrials.gov/study/NCT07244003","phase":"Phase 4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"recruiting","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","countries":["China"],"us_states":[]},{"nct":"NCT06361238","url":"https://clinicaltrials.gov/study/NCT06361238","phase":"Phase 3","title":"Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery","status":"recruiting","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","countries":["China"],"us_states":[]},{"nct":"NCT06374875","url":"https://clinicaltrials.gov/study/NCT06374875","phase":"Phase 4","title":"Fibrosis Lessens After Metabolic Surgery","status":"recruiting","sponsor":"The Cleveland Clinic","countries":["United States","Brazil","Canada","Finland","India","Ireland","Italy","Kuwait","Mexico","Spain","Sweden","Switzerland","United Kingdom"],"us_states":["Arizona","Indiana","Minnesota","Ohio"]},{"nct":"NCT06686134","url":"https://clinicaltrials.gov/study/NCT06686134","phase":"Not stated","title":"Comprehensive Clinical Evaluation Study of GLP-1RA","status":"recruiting","sponsor":"LI YAN","countries":["China"],"us_states":[]},{"nct":"NCT06720246","url":"https://clinicaltrials.gov/study/NCT06720246","phase":"Not stated","title":"Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity","status":"recruiting","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","countries":["Italy"],"us_states":[]},{"nct":"NCT07309094","url":"https://clinicaltrials.gov/study/NCT07309094","phase":"Not stated","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"recruiting","sponsor":"Cardenal Herrera University","countries":["Spain"],"us_states":[]},{"nct":"NCT05925959","url":"https://clinicaltrials.gov/study/NCT05925959","phase":"Not applicable","title":"Preoperative Weight Loss for Open Abdominal Wall Reconstruction","status":"recruiting","sponsor":"Benjamin T. Miller","countries":["United States"],"us_states":["Illinois","Ohio"]},{"nct":"NCT05681299","url":"https://clinicaltrials.gov/study/NCT05681299","phase":"Phase 4","title":"Effects of GH and Lirglutide on AgRP","status":"recruiting","sponsor":"Columbia University","countries":["United States"],"us_states":["New York"]},{"nct":"NCT05268237","url":"https://clinicaltrials.gov/study/NCT05268237","phase":"Phase 1/Phase 2","title":"Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus","status":"recruiting","sponsor":"Biolingus","countries":["Hong Kong"],"us_states":[]},{"nct":"NCT05390892","url":"https://clinicaltrials.gov/study/NCT05390892","phase":"Phase 4","title":"PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","status":"recruiting","sponsor":"Brigham and Women's Hospital","countries":["United States"],"us_states":["Alabama","Arizona","California","Florida","Georgia","Illinois","Iowa","Kansas","Maryland","Massachusetts","Michigan","Minnesota","Missouri","Nebraska","New York","North Carolina","Ohio","Oregon","Pennsylvania","Rhode Island","South Carolina","Tennessee","Texas","Virginia","Wisconsin"]},{"nct":"NCT04575844","url":"https://clinicaltrials.gov/study/NCT04575844","phase":"Phase 4","title":"Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome","status":"recruiting","sponsor":"University of Virginia","countries":["United States"],"us_states":["Virginia"]},{"nct":"NCT03883412","url":"https://clinicaltrials.gov/study/NCT03883412","phase":"Phase 4","title":"Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)","status":"recruiting","sponsor":"University of Virginia","countries":["United States"],"us_states":["Virginia"]},{"nct":"NCT03087032","url":"https://clinicaltrials.gov/study/NCT03087032","phase":"Phase 4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"recruiting","sponsor":"The First Affiliated Hospital of Xiamen University","countries":["China"],"us_states":[]},{"nct":"NCT03878706","url":"https://clinicaltrials.gov/study/NCT03878706","phase":"Not stated","title":"The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination","status":"recruiting","sponsor":"University of Athens","countries":["Greece"],"us_states":[]}],"aliases":["Victoza","Saxenda"],"summary":"A prescription drug that acts like the hormone GLP-1. FDA approved it as Victoza for type 2 diabetes and as Saxenda for weight loss.","citations":[{"n":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341","tier":"primary","type":"regulatory","title":"Drugs@FDA: Victoza injection, application 022341"},{"n":2,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321","tier":"primary","type":"regulatory","title":"Drugs@FDA: Saxenda injection, application 206321"},{"n":3,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","tier":"primary","type":"label","title":"DailyMed: Victoza injection prescribing information, revised October 2025"},{"n":4,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143","tier":"primary","type":"label","title":"DailyMed: Saxenda injection prescribing information, revised June 2026"},{"n":5,"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes","tier":"primary","type":"regulatory","title":"FDA: first generic referencing Victoza approved, 23 December 2024"},{"n":6,"url":"https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals","tier":"primary","type":"regulatory","title":"FDA: 2025 first generic drug approvals, including liraglutide referencing Saxenda"},{"n":7,"url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide%20Injection&st=c","tier":"primary","type":"regulatory","title":"FDA drug shortages: liraglutide injection, currently in shortage"},{"n":8,"url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list","tier":"primary","type":"regulatory","title":"FDA: proposal to exclude liraglutide from the 503B bulks list, 30 April 2026"},{"n":9,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize","tier":"primary","type":"regulatory","title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026"},{"n":10,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026","tier":"primary","type":"regulatory","title":"FDA warning letter to a website offering compounded liraglutide, 20 February 2026"},{"n":11,"url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html","tier":"primary","type":"regulatory","title":"FDA Import Alert 66-80: GLP-1 bulk drug substances, revised 9 October 2026"},{"n":12,"url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs","tier":"legal-analysis","type":"legal-analysis","title":"Orrick: FDA moves to end large-scale compounding of GLP-1 drugs"},{"n":13,"url":"https://www.mondaq.com/unitedstates/healthcare/1814666/fda-takes-aim-at-misleading-online-claims-for-compounded-glp-1-drugs","tier":"legal-analysis","type":"legal-analysis","title":"McDermott Will & Schulte, on Mondaq: FDA takes aim at online claims for compounded GLP-1 drugs"},{"n":14,"url":"https://pubmed.ncbi.nlm.nih.gov/27295427/","tier":"peer-reviewed","type":"rct","title":"LEADER: liraglutide and heart outcomes in type 2 diabetes, 2016"},{"n":15,"url":"https://pubmed.ncbi.nlm.nih.gov/26132939/","tier":"peer-reviewed","type":"rct","title":"SCALE: liraglutide 3.0 mg for weight management, 2015"},{"n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/31034184/","tier":"peer-reviewed","type":"rct","title":"Ellipse: liraglutide in children and teens with type 2 diabetes, 2019"},{"n":17,"url":"https://pubmed.ncbi.nlm.nih.gov/32233338/","tier":"peer-reviewed","type":"rct","title":"Liraglutide for teens with obesity, 2020"},{"n":18,"url":"https://pubmed.ncbi.nlm.nih.gov/41161684/","tier":"peer-reviewed","type":"systematic-review","title":"Cochrane review: liraglutide for adults living with obesity, 2025"},{"n":19,"url":"https://pubmed.ncbi.nlm.nih.gov/37672063/","tier":"peer-reviewed","type":"systematic-review","title":"Review and meta-analysis: liraglutide for weight in children and teens, 2023"},{"n":20,"url":"https://www.biospace.com/fda/teva-brings-first-glp-1-generic-for-obesity-targets-novos-saxenda","tier":"established-news","type":"reference","title":"BioSpace: first generic of Saxenda approved, August 2025"},{"n":21,"url":"https://www.healio.com/news/endocrinology/20250214/fda-approves-a-generic-form-of-liraglutide-to-treat-type-2-diabetes","tier":"established-news","type":"reference","title":"Healio: FDA approves a generic form of liraglutide for type 2 diabetes"}],"known_risks":["In rats and mice, liraglutide caused thyroid tumors. The labels tell people with a rare thyroid cancer, or that cancer in the family, not to use it [^3] [^4].","The most common problems are nausea, diarrhea, vomiting, less hunger, upset stomach and constipation [^3] [^4]. In a teen weight trial, about 1 in 10 on it stopped because of unwanted effects. Nobody on the dummy shot stopped [^17].","The labels warn of a swollen pancreas and gallbladder disease. They also warn of kidney harm from losing fluids, and of bad allergic reactions [^3] [^4].","Taken with insulin or some other diabetes drugs, it can push blood sugar too low. Children on Victoza had low blood sugar more often, even without insulin [^3].","Saxenda can raise the heart rate, and its label says to check it often. It may harm an unborn baby, so the label says to stop it in pregnancy [^4].","A 2025 review of 24 trials in adults with obesity found it may raise the chance of serious unwanted effects [^18]."],"short_answer":"Liraglutide is FDA-approved as Victoza and Saxenda, and as generics, with a prescription. The evidence grade is strong-human for blood sugar, weight and heart risk in diabetes. It is still on FDA's shortage list. Pharmacy copies are not approved.","evidence_grade":"strong-human","open_questions":["Nobody knows if it can cause thyroid cancer in people. The rodent studies do not tell us [^3] [^4].","A 2025 review rated the size of the weight loss as very uncertain. Most of its trials were paid for by the maker [^18].","Teens in a weight trial regained some of the loss once they stopped. The trial does not show what happens years later [^17].","In adults with obesity, the 2025 review could not tell if it changes the risk of death [^18].","Nobody knows how closely pharmacy copies match the approved drug. FDA does not approve them, and their raw powder may come from plants that broke its rules [^10] [^11]."],"section_routes":"The legal way to get liraglutide is a prescription for Victoza, Saxenda or an approved generic [^1] [^2] [^5] [^6]. Each brand label says who it is for and how it is taken [^3] [^4].\n\nSupply is still tight. Liraglutide is on FDA's shortage list, and the brands have limited supply [^7]. Saxenda is due to stop in January 2027 [^7]. The approved generic of Saxenda is for the same weight-loss use [^6].\n\nWhile the shortage lasts, outsourcing facilities may make copies from raw powder [^8] [^9]. FDA does not approve these copies [^10]. FDA has proposed ending that path, and the proposal is not final [^8].","regulatory_as_of":"2026-10-24","section_channels":"Liraglutide reaches people outside the approved brands and generics in three main ways [^10] [^11]. The first is copies made by pharmacies and outsourcing facilities. Pharmacies that make copies for one patient do not have to meet factory quality rules. So a problem in the raw powder may not be caught [^11]. The second is websites that offer these copies. In February 2026, FDA warned a website whose claims suggested its liraglutide copies were approved. Its pictured label also named a business that did not make the drug [^10]. In June 2026, FDA sent 25 more such letters, one of them about liraglutide [^13]. The third is raw powder shipped from other countries. FDA checked 48 sites that make raw GLP-1 powder. It found 21% broke its rules or did not answer its requests in time [^11]. Its border staff may hold such shipments without testing them [^11].\n\nFDA has not checked any of these copies for safety or whether they work [^10]. No FDA page we found names fake liraglutide, so this page does not describe that channel.","section_evidence":"The evidence grade is strong-human: large trials in people agree that it lowers blood sugar and weight [^14] [^15] [^16]. In a heart trial of 9,340 adults with type 2 diabetes and high heart risk, fewer people on it had a heart attack, a stroke or a heart death. Over about 4 years, that was 13.0% on it and 14.9% on a dummy shot [^14]. In a 56-week trial of 3,731 adults with obesity and no diabetes, people on it lost about 8.4 kg. People on the dummy shot lost about 2.8 kg [^15]. In a trial of 134 children aged 10 to 16 with type 2 diabetes, it lowered blood sugar more than a dummy shot over 52 weeks [^16]. In a 56-week trial of 251 teens with obesity, it lowered body size more than a dummy shot [^17].\n\nA 2025 review of 24 trials in adults with obesity found it likely helps more people lose at least 5% of their weight. It rated the size of the loss as very uncertain [^18]. A 2023 review of seven trials in children and teens found small drops in weight and blood sugar [^19].\n\nThe maker paid for these four trials, with government help on the heart trial [^14] [^15] [^16] [^17]. They tested the approved drug. They tell us nothing about copies made by pharmacies, which FDA has not approved [^10].","regulatory_status":"fda-approved","section_what_it_is":"Liraglutide is a prescription drug. It is made to act like GLP-1, a hormone the body makes [^3]. It helps the body control blood sugar, and it makes people eat less [^3] [^4]. FDA first approved it in 2010 [^1]. One company sells it under two brand names, and FDA has approved generic versions of both [^1] [^2] [^5] [^6].\n\nVictoza is a daily shot for type 2 diabetes [^3]. Saxenda is a daily shot for weight loss, used with diet and exercise [^4]. Both hold the same drug, so the labels say not to use them together [^3] [^4]. The body clears half of a dose in about 13 hours [^3]. That is why it is taken every day.\n\nSome pharmacies make their own copies of it. Those copies are not FDA-approved [^10].","section_is_it_legal":"Liraglutide is FDA-approved: FDA approved it as Victoza in January 2010 and as Saxenda in December 2014 [^1] [^2]. That covers the brand drugs and their approved generics, with a prescription, for the uses on their labels. It does not make copies from pharmacies approved [^10]. Checked 24 October 2026.\n\nVictoza is approved for type 2 diabetes, not for weight loss. Saxenda is the one approved for weight loss [^3] [^4]. FDA approved the first generic of Victoza in December 2024 [^5]. It approved the first generic of Saxenda in August 2025 [^6].\n\nLiraglutide has been on FDA's drug shortage list since July 2023, and it is still there [^7]. Generic versions are listed as available, and the brands have limited supply [^7]. The maker plans to stop making Saxenda in January 2027 [^7].\n\nWhile a drug is on that list, outsourcing facilities may make it from raw powder [^8] [^9]. In April 2026, FDA proposed keeping liraglutide off the list of raw ingredients those facilities may use. The proposal is not final [^8] [^12]. If it becomes final, they could not make it from raw powder once the shortage ends [^12]. FDA generally treats a drug as available once its shortage ends. A pharmacy then may not make regular copies of it [^9]. Every copy must meet the compounding rules in federal law, and a website may not suggest a copy is FDA-approved [^10].","unofficial_channels":[{"type":"compounding-outside-the-rules","what_it_is":"Copies of liraglutide made by pharmacies and outsourcing facilities, often from raw powder made abroad.","enforcement":[{"date":"2026-04-30","text":"FDA proposed keeping liraglutide off the list of raw ingredients outsourcing facilities may use. The proposal is not final.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"}],"legal_position":{"text":"Outsourcing facilities may make it from raw powder only while it is on FDA's shortage list or on their list of allowed ingredients. FDA has proposed keeping it off that list.","source_url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"},"documented_risks":[{"text":"FDA found that 21% of 48 sites making raw GLP-1 powder broke its manufacturing rules or did not answer its records requests in time.","source_url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html"},{"text":"Pharmacies compounding for one patient are exempt from factory quality rules, so FDA says a problem in the raw powder may not be caught.","source_url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html"}]},{"type":"telehealth","what_it_is":"Websites that offer compounded liraglutide straight to consumers.","enforcement":[{"date":"2026-02-20","text":"FDA warning letter to a website offering compounded liraglutide and semaglutide, for claims that suggested the copies were approved.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"}],"legal_position":{"text":"FDA says a site may not suggest a compounded copy is FDA-approved, or show a label naming a business that did not make it.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"},"documented_risks":[{"text":"FDA found a site whose pictured label named a business that did not make the drug, so buyers could not tell who made it.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"},{"text":"FDA says compounded copies are not approved and have not been checked for safety or whether they work.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"}]},{"type":"overseas-or-import","what_it_is":"Raw liraglutide powder shipped into the US from makers in other countries.","enforcement":[{"date":"2026-10-09","text":"FDA revised Import Alert 66-80, which covers raw liraglutide and other GLP-1 powders made abroad.","source_url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html"}],"legal_position":{"text":"FDA lets its border staff hold shipments of raw GLP-1 powder without testing them, unless the maker is on its list of plants that meet its rules.","source_url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html"},"documented_risks":[{"text":"FDA has seen sites register as GLP-1 powder makers, refuse its records requests, and then drop their registration within a short time.","source_url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html"}]}]},"provenance":{"name":{"fact_id":"7f00172a-f990-4266-b35b-ecdabfbe458a","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","source_type":"primary","captured_at":"2026-10-25T00:49:49.533Z","checked_at":"2026-10-25T06:23:45.904Z","confidence":1,"stale":false},"class":{"fact_id":"03fe248c-d3c9-4399-987f-4fc01445fa7a","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","source_type":"primary","captured_at":"2026-10-25T00:49:49.533Z","checked_at":"2026-10-25T06:23:45.906Z","confidence":1,"stale":false},"access":{"fact_id":"489b649b-46ca-48b2-9354-dd12dd66fb94","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341","source_type":"primary","captured_at":"2026-10-25T00:49:50.151Z","checked_at":"2026-10-25T06:23:45.870Z","confidence":1,"stale":false},"dosing":{"fact_id":"5e4ba1f8-af05-46d1-b5a3-072b35733f0b","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","source_type":"primary","captured_at":"2026-10-25T00:49:49.533Z","checked_at":"2026-10-25T06:23:45.883Z","confidence":1,"stale":false},"trials":{"fact_id":"c01615a6-eb59-4770-a84d-ea64814d41fd","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=liraglutide+OR+Victoza+OR+Saxenda&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-25T18:03:20.516Z","checked_at":"2026-10-25T18:03:20.516Z","confidence":1,"stale":false},"aliases":{"fact_id":"f2e2c0a5-3d12-4cba-9099-a62d2bcb22f3","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143","source_type":"primary","captured_at":"2026-10-25T00:49:49.628Z","checked_at":"2026-10-25T06:23:45.879Z","confidence":1,"stale":false},"summary":{"fact_id":"e6d6b632-442e-4cb5-92cb-a3855b422053","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143","source_type":"primary","captured_at":"2026-10-25T00:49:49.628Z","checked_at":"2026-10-25T06:23:45.896Z","confidence":1,"stale":false},"citations":{"fact_id":"0c504c7d-65e0-4b7e-9b00-33359af6d093","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","source_type":"primary","captured_at":"2026-10-25T00:49:49.533Z","checked_at":"2026-10-25T06:23:45.924Z","confidence":1,"stale":false},"known_risks":{"fact_id":"88a8d7ce-8972-4175-8fd9-ae456f001cbe","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","source_type":"primary","captured_at":"2026-10-25T00:49:49.533Z","checked_at":"2026-10-25T06:23:45.913Z","confidence":1,"stale":false},"short_answer":{"fact_id":"a55ff2ec-d4db-416d-98b5-b8d002b668fd","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-25T00:14:44.418Z","checked_at":"2026-10-25T06:23:45.908Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"d38ddbf5-a6b5-4e0e-85ae-2130489878f4","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-25T00:14:45.193Z","checked_at":"2026-10-25T06:23:45.912Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"2e53a54c-f60c-47d7-9d9b-608b2a44c719","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","source_type":"primary","captured_at":"2026-10-25T00:49:49.533Z","checked_at":"2026-10-25T06:23:45.915Z","confidence":1,"stale":false},"section_routes":{"fact_id":"d41dcbb5-f35b-4e36-9e29-f968862ae7d5","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341","source_type":"primary","captured_at":"2026-10-25T00:49:50.151Z","checked_at":"2026-10-25T06:23:45.920Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"3ed96565-663c-460c-bb5b-8453eb216057","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341","source_type":"primary","captured_at":"2026-10-25T00:49:50.151Z","checked_at":"2026-10-25T06:23:45.910Z","confidence":1,"stale":false},"section_channels":{"fact_id":"5487606a-40ab-4c39-b541-04edce9cd98f","source_url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html","source_type":"primary","captured_at":"2026-10-25T00:30:10.553Z","checked_at":"2026-10-25T06:23:45.921Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"bb8b596a-39bb-479d-853f-71444527315e","source_url":"https://pubmed.ncbi.nlm.nih.gov/27295427/","source_type":"peer-reviewed","captured_at":"2026-10-25T00:51:10.205Z","checked_at":"2026-10-25T06:23:45.918Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"e5771f63-3494-4f75-88a9-29530623df60","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321","source_type":"primary","captured_at":"2026-10-25T00:49:50.258Z","checked_at":"2026-10-25T06:23:45.889Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"b3231e2c-dc67-4c21-a2f1-c38cb9dc8f05","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","source_type":"primary","captured_at":"2026-10-25T00:49:49.533Z","checked_at":"2026-10-25T06:23:45.892Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"eb8338ab-6a50-48d1-a694-814d6b3bf133","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341","source_type":"primary","captured_at":"2026-10-25T00:49:50.151Z","checked_at":"2026-10-25T06:23:45.917Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"8c5c778e-428a-4008-8346-7fc7c4d7cfcb","source_url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html","source_type":"primary","captured_at":"2026-10-25T00:30:10.553Z","checked_at":"2026-10-25T06:23:45.901Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":3,"title":"DailyMed: Victoza injection prescribing information, revised October 2025","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"},{"n":4,"title":"DailyMed: Saxenda injection prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143"},{"n":17,"title":"Liraglutide for teens with obesity, 2020","url":"https://pubmed.ncbi.nlm.nih.gov/32233338/"},{"n":18,"title":"Cochrane review: liraglutide for adults living with obesity, 2025","url":"https://pubmed.ncbi.nlm.nih.gov/41161684/"}],"open_questions":[{"n":3,"title":"DailyMed: Victoza injection prescribing information, revised October 2025","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"},{"n":4,"title":"DailyMed: Saxenda injection prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143"},{"n":18,"title":"Cochrane review: liraglutide for adults living with obesity, 2025","url":"https://pubmed.ncbi.nlm.nih.gov/41161684/"},{"n":17,"title":"Liraglutide for teens with obesity, 2020","url":"https://pubmed.ncbi.nlm.nih.gov/32233338/"},{"n":10,"title":"FDA warning letter to a website offering compounded liraglutide, 20 February 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"},{"n":11,"title":"FDA Import Alert 66-80: GLP-1 bulk drug substances, revised 9 October 2026","url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html"}],"section_routes":[{"n":1,"title":"Drugs@FDA: Victoza injection, application 022341","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341"},{"n":2,"title":"Drugs@FDA: Saxenda injection, application 206321","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321"},{"n":5,"title":"FDA: first generic referencing Victoza approved, 23 December 2024","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes"},{"n":6,"title":"FDA: 2025 first generic drug approvals, including liraglutide referencing Saxenda","url":"https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals"},{"n":3,"title":"DailyMed: Victoza injection prescribing information, revised October 2025","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"},{"n":4,"title":"DailyMed: Saxenda injection prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143"},{"n":7,"title":"FDA drug shortages: liraglutide injection, currently in shortage","url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide%20Injection&st=c"},{"n":8,"title":"FDA: proposal to exclude liraglutide from the 503B bulks list, 30 April 2026","url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"},{"n":9,"title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"n":10,"title":"FDA warning letter to a website offering compounded liraglutide, 20 February 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"}],"section_channels":[{"n":10,"title":"FDA warning letter to a website offering compounded liraglutide, 20 February 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"},{"n":11,"title":"FDA Import Alert 66-80: GLP-1 bulk drug substances, revised 9 October 2026","url":"https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html"},{"n":13,"title":"McDermott Will & Schulte, on Mondaq: FDA takes aim at online claims for compounded GLP-1 drugs","url":"https://www.mondaq.com/unitedstates/healthcare/1814666/fda-takes-aim-at-misleading-online-claims-for-compounded-glp-1-drugs"}],"section_evidence":[{"n":14,"title":"LEADER: liraglutide and heart outcomes in type 2 diabetes, 2016","url":"https://pubmed.ncbi.nlm.nih.gov/27295427/"},{"n":15,"title":"SCALE: liraglutide 3.0 mg for weight management, 2015","url":"https://pubmed.ncbi.nlm.nih.gov/26132939/"},{"n":16,"title":"Ellipse: liraglutide in children and teens with type 2 diabetes, 2019","url":"https://pubmed.ncbi.nlm.nih.gov/31034184/"},{"n":17,"title":"Liraglutide for teens with obesity, 2020","url":"https://pubmed.ncbi.nlm.nih.gov/32233338/"},{"n":18,"title":"Cochrane review: liraglutide for adults living with obesity, 2025","url":"https://pubmed.ncbi.nlm.nih.gov/41161684/"},{"n":19,"title":"Review and meta-analysis: liraglutide for weight in children and teens, 2023","url":"https://pubmed.ncbi.nlm.nih.gov/37672063/"},{"n":10,"title":"FDA warning letter to a website offering compounded liraglutide, 20 February 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"}],"section_what_it_is":[{"n":3,"title":"DailyMed: Victoza injection prescribing information, revised October 2025","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"},{"n":4,"title":"DailyMed: Saxenda injection prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143"},{"n":1,"title":"Drugs@FDA: Victoza injection, application 022341","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341"},{"n":2,"title":"Drugs@FDA: Saxenda injection, application 206321","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321"},{"n":5,"title":"FDA: first generic referencing Victoza approved, 23 December 2024","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes"},{"n":6,"title":"FDA: 2025 first generic drug approvals, including liraglutide referencing Saxenda","url":"https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals"},{"n":10,"title":"FDA warning letter to a website offering compounded liraglutide, 20 February 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"}],"section_is_it_legal":[{"n":1,"title":"Drugs@FDA: Victoza injection, application 022341","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341"},{"n":2,"title":"Drugs@FDA: Saxenda injection, application 206321","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321"},{"n":10,"title":"FDA warning letter to a website offering compounded liraglutide, 20 February 2026","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/levity-inc-dba-levity-717990-02202026"},{"n":3,"title":"DailyMed: Victoza injection prescribing information, revised October 2025","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"},{"n":4,"title":"DailyMed: Saxenda injection prescribing information, revised June 2026","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143"},{"n":5,"title":"FDA: first generic referencing Victoza approved, 23 December 2024","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes"},{"n":6,"title":"FDA: 2025 first generic drug approvals, including liraglutide referencing Saxenda","url":"https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals"},{"n":7,"title":"FDA drug shortages: liraglutide injection, currently in shortage","url":"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide%20Injection&st=c"},{"n":8,"title":"FDA: proposal to exclude liraglutide from the 503B bulks list, 30 April 2026","url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list"},{"n":9,"title":"FDA: policies for compounders as GLP-1 supply stabilizes, updated 1 April 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize"},{"n":12,"title":"Orrick: FDA moves to end large-scale compounding of GLP-1 drugs","url":"https://www.orrick.com/en/Insights/2026/05/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/v2/studies?query.intr=liraglutide+OR+Victoza+OR+Saxenda&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143","https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/27295427/","https://www.accessdata.fda.gov/CMS_IA/importalert_1186.html","https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341","https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321"],"verified_at":"2026-10-25T06:23:45.924Z","published_at":"2026-10-25T18:23:24.687Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-25T18:03:20.516Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}